Results 111 to 120 of about 27,539 (246)

[Allergic conjunctivitis].

Boletin medico del Hospital Infantil de Mexico, 1993
The eye reacts to foreign substances through a variety of specific and non-specific defense mechanisms. Constantly exposed to a great variety of microorganisms, the eye is capable of protecting itself without altering its own structure and function. Its resistance relies upon anatomic and physiological properties of its external components (eyelids ...
B E, Del Río-Navarro, J J, Sienra-Monge, A, Castellanos, M J, Williams-Gotti   +3 more
openaire   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Clinical Ophthalmology, 2009
Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology,
Arthur B Epstein, Peter T Van Hoven, Alan Kaufman, Warner W Carr   +3 more
doaj  

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Fexofenadine is Efficacious and Safe in Children (Aged 6-11 Years) with Seasonal Allergic Rhinitis [PDF]

, 2003
Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H1-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period ...
Bachert, C, Baena-Cagnani, C, Decosta, P, Finn, A, Hedlin, G, Kowalski, M, Meltzer, E, Potter, P, Rosado-Pinto, J, Ruuth, E, Scheinmann, P, Simons, F, Wahn, U   +12 more
core  

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham, Mahreen Ameen, H. Chih‐ho Hong, Norito Katoh, Richard G. Langley, Ketty Peris, Kristian Reich, Juan F. Silvestre, Eric Simpson, Thomas Werfel, Le Gjerum, Ann‐Marie Tindberg, Christian Bjerregård Øland, Andrew Blauvelt   +13 more
wiley   +1 more source

A Review of the Differential Diagnosis of Acute Infectious Conjunctivitis: Implications for Treatment and Management

Clinical Ophthalmology, 2020
Elizabeth Yeu,1 Scott Hauswirth2 1Virginia Eye Consultants, Norfolk, VA, USA; 2Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, USACorrespondence: Elizabeth YeuVirginia Eye Consultants ...
Yeu E, Hauswirth S
doaj  

Sleep and Trajectories of Respiratory and Allergic Symptoms Between 1 and 5.5 Years of Age in the Elfe Birth Cohort

Journal of Sleep Research, EarlyView.
ABSTRACT Sleep troubles and respiratory and allergic health issues are associated in children, but the timeline of their association is overlooked. This study investigates the associations between sleep patterns at age 1 and respiratory and allergic multi‐trajectories (RespA‐MTG) between ages 1 and 5.5, and the associations between these multi ...
Daniele Saade, Rosalie Delvert, Chantal Raherison‐Semjen, Orianne Dumas, Mohammed Sedki, Marie‐Noëlle Dufourg, Blandine de Lauzon‐Guillain, Bénédicte Leynaert, Rachel Nadif, Annabelle Bédard, Sabine Plancoulaine   +10 more
wiley   +1 more source

Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis [PDF]

, 2017
Dahdah, Lamia, Fiocchi, Alessandro, Mennini, Maurizio   +2 more
core   +1 more source